All GLG News Analyses Filed Under: Oncology

This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!

Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???

This drug, which has just entered Phase I testing, is very interesting because it combines IL-12, which has shown both activity and significant toxicity, with a targeting antibody. Hopefully, this targeting antibody will minimize the toxicity of IL-12 on or in normal tissues.

The failure of this study has wide ranging implications for Pfizer and other melanoma trials. This drug, which only a few years ago caused much excitement in the melanoma oncology community, failed to show any survival benefit in this Phase III trial, when compared to standard, but generally ineffective,...

While disappointing for patients and caregivers, Pfizer's loss of a late-stage treatment for melanoma casts an even darker shadow on the ability of pharmaceutical and biotech companies to successfully bring new treatments to market. Coupled with other recent Phase 3 failures, this latest outcome points...

This article is briefly stating the future hold of Pfizer in developing drugs for cancer treatment. The infomation provided is incompleted, for example, there is an absence of detailed information on the phase III clinical trial neccesary to know if there is a flaw in the...

Gene driven nicotine receptors will predispose to increased smoking. What will this lead to?? Increased addiction due to mutations increases cancer risk.

SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System.  These advantages include: 1.  Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...

Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)

Biological efficacy has been shown for a number of cancer vaccines. Clinical efficacy has been shown in few of them. Clinical benefit just in one: idiotype vaccine for B-cell lymphoma. TroVax still has to clear the last hurdle, and likely also the second one.